Engineered immune cells take on tough blood cancers
NCT ID NCT03233854
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-stage study tests a treatment made from a patient's own immune cells, modified to recognize and attack cancer cells that have returned or not responded to standard therapy. The treatment is given with chemotherapy and an immune-boosting drug. The main goals are to check safety and find the best dose in adults with certain types of B-cell leukemia or lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
Conditions
Explore the condition pages connected to this study.